We conducted two replicate 52-week , randomized , double-blind , phase 3 trials ( INPULSIS-1 and INPULSIS-2 ) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis .